{
  "id": "everyday#screening_cues_43f9c3d9",
  "title_en": "General — Screening Cues",
  "title_vi": "General — Dấu hiệu sàng lọc",
  "text_en": "strategic was considered, GRADE tables, narrative descriptions synergy with the WHO Comprehensive mental health of the evidence that was not inserted into GRADE action plan 2013–2030 (14). It includes additional tables and considerations on preferences, values and details that are beyond the scope of the guideline, feasibility issues. such as optimal duration of therapy, maximum daily Relevant departments in ministries of health will dose, when to stop the therapy, when to refer, default be notified of the updated guideline through WHO criteria, toxicity and drug–drug interactions. This regional and country offices. A briefing package will mhGAP guideline will be similarly incorporated into be prepared for technical officers outside of WHO other mhGAP implementation materials, including headquarters, including an executive summary and mhGAP humanitarian intervention guide (mhGAP-HIG) a Q&A document related to policy and programme (218), mhGAP-IG App (e-mhGAP), mhGAP training implications. In particular, the briefing materials manuals (219), mhGAP operations manual (209), will highlight the changes (updates) and the new mhGAP community toolkit (220) and the mhGAP recommendations presented in this guideline. e-learning course, which is being developed with the WHO Academy. The media will be notified of the updated mhGAP guideline. Capacity-building activities will be 4.3 WHO model list of undertaken through regional and subregional essential medicines (EML) meetings and other activities related to mhGAP and implementation of four WHO action plans: the The EML and EMLc includes products for MNS disorders Comprehensive mental health action plan 2021–2030 in the areas of psychotic disorders, mood disorders, (14), the Intersectoral global action plan on epilepsy anxiety, substance use and epilepsy (13,132). The and other neurological disorders 2022–2031 (3), the updated recommendations for any psychotropic Global action plan on the public health response to medicines will be used to inform the EML and EMLc dementia 2017–2025 (15), and the Global alcohol action and to promote affordable access to quality, safe and plan 2022–2030 (16). effective medicines for MNS disorders. 16 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre 112",
  "gloss_vi": "Strategic was considered, grade tables, narrative descriptions synergy with the who comprehensive mental health of the evidence that was not inserted into grade action plan 2013–2030 (14). it includes additional tables a...",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "screening_cues",
      "referral"
    ],
    "life_topics": [],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Screening Cues General — Dấu hiệu sàng lọc strategic was considered, GRADE tables, narrative descriptions synergy with the WHO Comprehensive mental health of the evidence that was not inserted into GRADE action plan 2013–2030 (14). It includes additional tables and considerations on preferences, values and details that are beyond the scope of the guideline, feasibility issues. such as optimal duration of therapy, maximum daily Relevant departments in ministries of health will dose, when to stop the therapy, when to refer, default be notified of the updated guideline through WHO criteria, toxicity and drug–drug interactions. This regional and country offices. A briefing package will mhGAP guideline will be similarly incorporated into be prepared for technical officers outside of WHO other mhGAP implementation materials, including headquarters, including an executive summary and mhGAP humanitarian intervention guide (mhGAP-HIG) a Q&A document related to policy and programme (218), mhGAP-IG App (e-mhGAP), mhGAP training implications. In particular, the briefing materials manuals (219), mhGAP operations manual (209), will highlight the changes (updates) and the new mhGAP community toolkit (220) and the mhGAP recommendations presented in this guideline. e-learning course, which is being developed with the WHO Academy. The media will be notified of the updated mhGAP guideline. Capacity-building activities will be 4.3 WHO model list of undertaken through regional and subregional essential medicines (EML) meetings and other activities related to mhGAP and implementation of four WHO action plans: the The EML and EMLc includes products for MNS disorders Comprehensive mental health action plan 2021–2030 in the areas of psychotic disorders, mood disorders, (14), the Intersectoral global action plan on epilepsy anxiety, substance use and epilepsy (13,132). The and other neurological disorders 2022–2031 (3), the updated recommendations for any psychotropic Global action plan on the public health response to medicines will be used to inform the EML and EMLc dementia 2017–2025 (15), and the Global alcohol action and to promote affordable access to quality, safe and plan 2022–2030 (16). effective medicines for MNS disorders. 16 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre 112 Strategic was considered, grade tables, narrative descriptions synergy with the who comprehensive mental health of the evidence that was not inserted into grade action plan 2013–2030 (14). it includes additional tables a..."
}